Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PPBT
PPBT logo

PPBT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Purple Biotech Ltd (PPBT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.550
1 Day change
-2.52%
52 Week Range
29.000
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

PPBT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock shows a mild near-term technical bounce, but the broader trend is still bearish, there is no strong catalyst from news or insider activity, and there is no supportive Wall Street or proprietary trading signal to justify an immediate buy.

Technical Analysis

The technical picture is mixed but weak overall. MACD histogram is positive and expanding, which suggests short-term momentum improvement. However, RSI_6 at 36.7 is only neutral-to-weak, and the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, indicating the longer trend is still down. Price at 1.7057 is just below pivot 1.727 and above support at 1.636, so the stock is trading near a decision zone rather than in a clear uptrend. The modeled near-term tendency is also modest: about -0.08% next day, +1.31% next week, and +1.75% next month, which is not strong enough for an immediate long-term buy.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options data is not very informative here because activity is extremely light. Call open interest is 400 versus put open interest of 1, and both put-call ratios are 0.0 due to no meaningful traded volume. Implied volatility is elevated with IV rank at 100 and IV percentile at 97.61, which usually reflects a highly speculative setup. This favors short-term volatility trading more than a beginner-friendly long-term entry.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
2

Positive Catalysts

  • ["MACD histogram is positive and expanding, showing improving short-term momentum.", "Price is holding above the nearest support area at 1.636.", "No recent negative news was reported in the last week."]

Neutral/Negative Catalysts

  • ["No news catalysts in the recent week.", "Hedge funds are neutral and insiders are neutral, with no significant accumulation signals.", "No AI Stock Picker signal today.", "No SwingMax signal recently.", "Bearish moving average structure remains in place.", "Options data shows very low actual trading interest and extremely high implied volatility.", "No recent congress trading data available.", "No significant analyst upgrades, target increases, or favorable sentiment data provided."]

Financial Performance

No usable latest-quarter financial snapshot was provided because of the data error, so there is no reliable quarterly revenue, earnings, or growth trend to support a long-term buy decision. The latest season cannot be confirmed from the dataset.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating trend or price target change data was provided, so Wall Street sentiment cannot be described as positive. Based on the available information, the analyst side appears neutral to lacking conviction, with no visible bull case from upgrades or target raises.

Wall Street analysts forecast PPBT stock price to rise
1 Analyst Rating
Wall Street analysts forecast PPBT stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.590
sliders
Low
34
Averages
34
High
34
Current: 1.590
sliders
Low
34
Averages
34
High
34
H.C. Wainwright
Emily Bodnar
Buy
downgrade
$34 -> $30
AI Analysis
2026-03-13
Reason
H.C. Wainwright
Emily Bodnar
Price Target
$34 -> $30
AI Analysis
2026-03-13
downgrade
Buy
Reason
H.C. Wainwright analyst Emily Bodnar lowered the firm's price target on Purple Biotech to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4 earnings and provided a corporate update, highlighting recent progress for the company's preclinical CAPTN-3 tri-specific T cell engager programs, the analyst tells investors in a research note. The firm said it expects additional updates regarding progress of the investigational new drug submission and plans for Phase 1 throughout 2026. The firm added that its new price target is based on a discounted cash flow analysis.

People Also Watch